Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1988-11-21
|
pubmed:abstractText |
alpha IR-3 is a mouse monoclonal antibody that binds to an epitope on the human insulin-like growth factor I (IGF-I) receptor and inhibits [125I]IGF-I binding to this receptor on human skin fibroblasts (HSF) and Hep G2 human hepatoblastoma cells. Unlike the natural ligand (IGF-I), neither intact alpha IR-3 nor its monovalent Fab fragment stimulate aminoisobutyric acid (AIB) uptake in HSF, and both competitively antagonize IGF-I's ability to produce this effect. However, when HSF are incubated with alpha IR-3 or its Fab' fragment, subsequent exposure to anti-mouse immunoglobulin G (IgG) produces a potent stimulation of AIB uptake. Anti-Mouse IgG by itself does not effect AIB uptake. alpha IR-3 also antagonizes IGF-I's ability to stimulate glycogen synthesis in Hep G2 cells. As with AIB uptake in HSF, the combination of alpha IR-3 followed by anti-mouse IgG stimulates glycogen synthesis in Hep G2 cells to the same extent as that produced by IGF-I. The triggering of these two biological effects depends on the concentration of both alpha IR-3 and anti-mouse IgG. These results are consistent with the possibility that local aggregation or cross-linking of IGF-I receptors plays an important role in transmembrane signaling by this receptor.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-aminoisobutyric acid,
http://linkedlifedata.com/resource/pubmed/chemical/Aminoisobutyric Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatomedin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0888-8809
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
831-7
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:2459608-Aminoisobutyric Acids,
pubmed-meshheading:2459608-Animals,
pubmed-meshheading:2459608-Antibodies, Monoclonal,
pubmed-meshheading:2459608-Cell Line,
pubmed-meshheading:2459608-Epitopes,
pubmed-meshheading:2459608-Humans,
pubmed-meshheading:2459608-Immunoglobulin G,
pubmed-meshheading:2459608-Liver Neoplasms, Experimental,
pubmed-meshheading:2459608-Mice,
pubmed-meshheading:2459608-Receptor, Insulin,
pubmed-meshheading:2459608-Receptors, Somatomedin,
pubmed-meshheading:2459608-Signal Transduction
|
pubmed:year |
1988
|
pubmed:articleTitle |
Evidence that receptor aggregation may play a role in transmembrane signaling through the insulin-like growth factor-I receptor.
|
pubmed:affiliation |
Charles A. Dana Research Institute, Boston, Massachusetts.
|
pubmed:publicationType |
Journal Article
|